OPWEF yields 2820.87% · PFE yields 6.13%● Live data
📍 OPWEF pulled ahead of the other in Year 1
Combined, OPWEF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OPWEF + PFE for your $10,000?
Opawica Explorations Inc., a junior resource company, engages in the acquisition, exploration, and evaluation of mineral properties in Canada. It explores for gold and base metal deposits. The company holds 100% interests in the Arrowhead property that consists of 19 mineral claims covering an area of 400.76 hectares located in the Joannes Township, Quebec; and the Bazooka property, which comprises 41 mineral claims covering an area of 1320.92 hectares located in the Beauchastel Township, Quebec. It also holds 100% interests in the Richard Copper property that includes 4 mineral claims located to Rouyn Noranda, Quebec, as well as in the Lil d'Espoir Lake property, which comprises 176 mineral claims covering an area of approximately 44 square kilometers; and the Chapel Island property consisting of 173 mineral claims covering an area of approximately 43.25 square kilometers located in the Exploits Subzone of Central Newfoundland and Labrador. In addition, the company holds 70% interests in the Density, Eclipse, and Mass properties that includes 906 mineral claims located in Newfoundland and Labrador. It also holds an option to acquire a 100% interest in Enterprise property, which comprises 308 mineral claims located in the Exploits Subzone of Central Newfoundland and Labrador. Opawica Explorations Inc. was incorporated in 1975 and is based in Vancouver, Canada.
Full OPWEF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.